Marc Bonneville, D.V.M. and CNRS research director, is currently the CSO of Institut Merieux, a holding dedicated to the development of diagnostic and therapeutic tools in the fields of infectious diseases, cancer and food safety. He was formerly the director of the INSERM Cancer Research Center Nantes / Angers (France). MB started to work in 1983 on transplantation immunology in Nantes (France), and then switched from 1987 to 1989 to analysis of mouse cellular immune responses during his postdoctoral training in S. Tonegawa’s laboratory (MIT, Boston). From 1990 to 2013, he has been heading a research group working on human cellular immune responses, with a main focus on γδ and NKT cells, and virus-specific conventional T cell responses. He is a co-founder of Innate Pharma SA, a biotech company that implements new immunotherapies targeting innate lymphocytes in infectiology and oncology. MB has authored around 200 scientific papers and 8 patents.